PIK3CA and neoplasm: Multiple mechanisms for trastuzumab therapy resistance have been proposed, but because the anti-tumour activity of HER2 inhibition at least partly depends on inhibition of the downstream phosphatidylinositol 3-kinase (PI3K) pathway, aberrant activation of this pathway can contribute to trastuzumab resistance [7,8].